We are live on
!
Find out more
TC
TFS Capital Portfolio holdings
AUM
$255M
1-Year Est. Return
32.31%
This Fund
S&P 500
This Quarter
Est. Return
-0.66%
1 Year Est. Return
+32.31%
3 Year Est. Return
+53.79%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$694M
AUM Growth
-$235M
(-25%)
Cap. Flow
-$209M
Cap. Flow
% of AUM
-30.05%
Top 10 Holdings %
Top 10 Hldgs %
4.41%
Holding
1,236
New
502
Increased
176
Reduced
298
Closed
257
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$2.36M |
| 2 |
Collegium Pharmaceutical
COLL
|
+$2.32M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.29M |
| 4 |
HSII
Heidrick & Struggles
HSII
|
+$2.25M |
| 5 |
HTCH
HUTCHINSON TECHNOLOGY INC
HTCH
|
+$2.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Emergent Biosolutions
EBS
|
+$5.99M |
| 2 |
Commercial Metals
CMC
|
+$5.95M |
| 3 |
Benchmark Electronics
BHE
|
+$5.84M |
| 4 |
Upbound Group
UPBD
|
+$5.71M |
| 5 |
FreightCar America
RAIL
|
+$5.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.04% |
| 2 | Industrials | 15.17% |
| 3 | Technology | 12.86% |
| 4 | Consumer Discretionary | 12.11% |
| 5 | Financials | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGTC
26
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.36M | 0.34% |
168,524
-124,112
| -42% | -$1.82M |
|
27
Seneca Foods Class A
SENEA
$1.13B
| $2.34M | 0.34% |
67,464
-18,337
| -21% | -$557K |
|
|
28
Collegium Pharmaceutical
COLL
$1.14B
| $2.31M | 0.33% |
+127,568
| New | +$2.32M |
|
|
HTCH
29
DELISTED
HUTCHINSON TECHNOLOGY INC
HTCH
| $2.31M | 0.33% |
631,629
+596,398
| +1,693% | +$2.17M |
|
30
John B. Sanfilippo & Son
JBSS
$949M
| $2.31M | 0.33% |
33,444
-14,587
| -30% | -$911K |
|
|
EGN
31
DELISTED
Energen
EGN
| $2.31M | 0.33% |
+63,136
| New | +$1.96M |
|
32
Alpha and Omega Semiconductor
AOSL
$923M
| $2.3M | 0.33% |
+194,458
| New | +$2.05M |
|
|
PDCE
33
DELISTED
PDC Energy, Inc.
PDCE
| $2.3M | 0.33% |
38,703
+24,687
| +176% | +$1.29M |
|
|
YELL
34
DELISTED
Yellow Corporation Common Stock
YELL
| $2.28M | 0.33% |
244,671
-207,517
| -46% | -$1.97M |
|
|
CPHD
35
DELISTED
Cepheid Inc
CPHD
| $2.25M | 0.32% |
67,286
-95,123
| -59% | -$2.99M |
|
|
BBOX
36
DELISTED
Black Box Corp
BBOX
| $2.22M | 0.32% |
+164,623
| New | +$1.77M |
|
37
Andersons Inc
ANDE
$2.65B
| $2.21M | 0.32% |
+70,480
| New | +$2M |
|
38
Babcock & Wilcox
BW
$1.43B
| $2.21M | 0.32% |
+10,348
| New | +$2.06M |
|
39
AngioDynamics
ANGO
$562M
| $2.2M | 0.32% |
178,782
+26,257
| +17% | +$290K |
|
40
UFP Industries
UFPI
$4.97B
| $2.17M | 0.31% |
76,002
+44,280
| +140% | +$1.05M |
|
|
PGEM
41
DELISTED
Ply Gem Holdings, Inc.
PGEM
| $2.17M | 0.31% |
154,584
+57,252
| +59% | +$613K |
|
|
APOL
42
DELISTED
Apollo Education Group Inc Class A
APOL
| $2.16M | 0.31% |
262,737
+70,625
| +37% | +$562K |
|
|
SYNH
43
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.16M | 0.31% |
52,349
-33,215
| -39% | -$1.37M |
|
|
SGNT
44
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $2.15M | 0.31% |
177,003
+29,738
| +20% | +$417K |
|
|
TPCO
45
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $2.14M | 0.31% |
277,150
+237,759
| +604% | +$1.92M |
|
|
TAST
46
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $2.14M | 0.31% |
148,026
-183,786
| -55% | -$2.4M |
|
|
MASI
47
DELISTED
Masimo
MASI
| $2.13M | 0.31% |
51,011
+31,247
| +158% | +$1.18M |
|
|
RPTP
48
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $2.11M | 0.3% |
459,546
-18,338
| -4% | -$73.7K |
|
|
CMD
49
DELISTED
Cantel Medical Corporation
CMD
| $2.11M | 0.3% |
29,606
-15,213
| -34% | -$955K |
|
|
GHDX
50
DELISTED
Genomic Health, Inc.
GHDX
| $2.11M | 0.3% |
85,095
+22,873
| +37% | +$628K |
|
Similar funds
KC
IPC
ECPI
FRM
WFG
IFB
KL
RP
TFS Capital's Q1 2016 Portfolio in Review
As of Q1 2016, TFS Capital held 1,236 positions worth $694M, down 25% from $929M the previous quarter. Its ten largest holdings account for 4.4% of the portfolio.
TFS Capital withdrew a net $209M in Q1 2016, closing 257 positions and reducing 298 holdings. Its most notable exit was Benchmark Electronics, an estimated $5.84M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 22% a quarter earlier, followed by Industrials and Technology.
Against the trend, TFS Capital opened a new position in Collegium Pharmaceutical worth $2.31M.
- TFS Capital's largest Q1 2016 buy was Collegium Pharmaceutical: 127,568 shares worth $2.31M.
- TFS Capital added most to Infinity Pharmaceuticals, Inc. in Q1 2016, an estimated $2.36M increase.
- TFS Capital's biggest Q1 2016 reduction was Emergent Biosolutions, cutting an estimated $5.99M.
- TFS Capital fully exited Benchmark Electronics in Q1 2016, selling an estimated $5.84M.
- TFS Capital's ten largest holdings make up 4.4% of its $694M portfolio in Q1 2016.
- TFS Capital opened 502 new positions and closed 257 in Q1 2016.
- TFS Capital's portfolio value fell 25% quarter-over-quarter to $694M.
Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.